Durvalumab Plus Chemotherapy Improves Survival in Advanced Biliary Tract Cancer

Hi Keivan,

I looked at the description of the referenced trial posted on clinicaltrials.gov.  There is no mention of requiring a PDL1 or MSH status to enroll.  Some trials include a more general population then test participants along the way to examine how the treatment being tested affects different groups.  If you search the NCT number (NCT03875235) on the clinicaltrials.gov website, you can see the eligibility and other information associated with the trial.

Regards, Mary